TY - JOUR
T1 - Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2
T2 - 67% complete regressions after 20 months of follow-up
AU - Willem Den Otter, F. W.
AU - Hill, Graham
AU - Klein, Wim R.
AU - Koten, Jan Willem
AU - Steerenberg, Peter A.
AU - De Mulder, Pieter H M
AU - Rhode, Christopher
AU - Stewart, Rachel
AU - Faber, Joop A J
AU - Ruitenberg, E. Joost
AU - Rutten, Victor P M G
PY - 1995/1/1
Y1 - 1995/1/1
N2 - We have tested the therapeutic potency of peritumorally injected low doses of interleukin-2(IL-2). Seventy tumours of the bovine ocular squamous-cell carcinoma (BOSCC), 1-3 cm in diameter, were treated with 5000, 20 000 or 200 000 U IL-2 from Eurocetus (Chiron) to find the optimal dose for treatment. Injections were given peritumorally on Monday to Friday on 2 consecutive weeks. The size of the tumours was measured before treatment and 1, 3, 4, 9 and 20 months after treatment. After 9 months complete regression was observed in 89% of the tumours treated with 5000 U IL-2, 80% treated with 20 000 U and 67% treated with 200 000 U. After 20 months, there was complete regression of 35%, 31% and 67% of the tumours respectively. The 9-and 20-month results of the 200 000-U treatment are significantly better than those of the 5000-U and 20 000-U treatments taken together. This protocol may be useful to treat advanced inoperable tumours (e.g. of the nasopharynx or skin) of human patients.
AB - We have tested the therapeutic potency of peritumorally injected low doses of interleukin-2(IL-2). Seventy tumours of the bovine ocular squamous-cell carcinoma (BOSCC), 1-3 cm in diameter, were treated with 5000, 20 000 or 200 000 U IL-2 from Eurocetus (Chiron) to find the optimal dose for treatment. Injections were given peritumorally on Monday to Friday on 2 consecutive weeks. The size of the tumours was measured before treatment and 1, 3, 4, 9 and 20 months after treatment. After 9 months complete regression was observed in 89% of the tumours treated with 5000 U IL-2, 80% treated with 20 000 U and 67% treated with 200 000 U. After 20 months, there was complete regression of 35%, 31% and 67% of the tumours respectively. The 9-and 20-month results of the 200 000-U treatment are significantly better than those of the 5000-U and 20 000-U treatments taken together. This protocol may be useful to treat advanced inoperable tumours (e.g. of the nasopharynx or skin) of human patients.
KW - Cancer
KW - IL-2 therapy
KW - Immunotherapy Bovine ocular squamous-cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=0029127881&partnerID=8YFLogxK
U2 - 10.1007/BF01788954
DO - 10.1007/BF01788954
M3 - Article
C2 - 7641215
AN - SCOPUS:0029127881
SN - 0340-7004
VL - 41
SP - 10
EP - 14
JO - Cancer Immunology Immunotherapy
JF - Cancer Immunology Immunotherapy
IS - 1
ER -